参考文献/References:
［1］ WONG T Y,CHEUNG C M,LARSEN M,SHARMA S,SIMO R.Diabetic retinopathy［J］.Nat Rev Dis Primers，2016,2:16012.
［2］ 杨宇，田敏，吕红彬.糖尿病视网膜病变的治疗进展［J］.眼科新进展，2015,35（5）:495-500.
YANG Y,TIAN M,L H B.Recent advances in treatment of diabetic retinopathy［J］.Rec Adv Ophthalmol,2015,35(5):495-500.
［3］ LECHNER J,O’LEARY O E,STITT A W.The pathology associated with diabetic retinopathy［J］.Vision Res，2017,139:7-14.
［4］ AMOAKU W M，GHANCHI F,BAILEY C,BANERJEE S,BANERJEE S,DOWNEY L,et al.Diabetic retinopathy and diabetic macular oedema pathways and management:UK Consensus Working Group［J］.Eye,2020,34(Suppl 1):1-51.
［5］ SAXENA R，SINGH D,SAKLANI R,GUPTA S K.Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy:current status and future prospects［J］.Eye Brain,2016,19(8):1-13.
［6］ WANG W,LO A C Y.Diabetic retinopathy:pathophysiology and treatments［J］.Int J Mol Sci,2018,19(6):1816.
［7］ RAJALAKSHMI R,PRATHIBA V,MOHAN V.Does tight control of systemic factors help in the management of diabetic retinopathy?［J］.Indian J Ophthalmol，2016,64(1):62-68.
［8］ AGROIYA P, ALRAWAHI A H.Pediatric diabetic retinopathy:experience of a tertiary hospital in oman［J］.Middle East Afr J Ophthalmol,2020,26(4):189-195.
［9］ MEHTA H, HENNINGS C, GILLIES M C, NGUYEN V, CAMPAIN A, FRASER-BELL S.Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema［J］.Cochrane Database Syst Rev，2018,4(4):CD011599.
［10］ POLIZZI S,MAHAJAN V B.Intravitreal anti-VEGF injections in pregnancy:case series and review of literature［J］.J Ocul Pharmacol Ther,2015,31(10):605-610.
［11］ ROSENTHAL J M,JOHNSON M W.Management of retinal diseases in pregnant patients［J］.J Ophthalmic Vis Res，2018,13(1):62-65.
［12］ TAO Y, JONAS J B.Intravitreal triamcinolone［J］.Ophthalmologic,2011,225(1):1-20.
［13］ FAZELAT A，LASHKARI K.Off-label use of intravitreal triamcinolone acetonide for diabetic macular edema in a pregnant patient［J］.Clin Ophthalmol,2011,5:439-441.
［14］ VIRGILI G,MENCHINI F,CASAZZA G,HOGG R,DAS R R,WANG X,et al.Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy［J］.Cochrane Database Syst Rev,2015,1:CD008081.
［15］ CAI S,YANG Q,LI X,ZHANG Y.The efficacy and safety of aflibercept and conbercept in diabetic macular edema［J］.Drug Des Devel Ther,2018,12:3471-3483.
［16］ ASHRAF M,SOUKA A,ADELMAN R,FORSTER S H.Aflibercept in diabetic macular edema:evaluating efficacy as a primary and secondary therapeutic option［J］.Eye，2016,30(12):1531-1541.
［17］ SUN J K,JAMPOL L M,INUSAH S.The diabetic retinopathy clinical research network (DRCR.net) and its contributions to the treatment of diabetic retinopathy［J］.Ophthalmic Res,2019,62(4):225-230.
［18］ Writing Committee for the Diabetic Retinopathy Clinical Research Network,GROSS J G,GLASSMAN A R,JAMPOL L M，INUSAH S.Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy:a randomized clinical trial［J］.JAMA,2015,314(20):2137-2146.
［19］ LI J,PAULUS Y M.Advances in retinal laser therapy［J］.Int J Ophthalmic Res，2018,4(1):259-264.
［20］ BRESSLER S B,BEAULIEU W T,GLASSMAN A R，GROSS J G.Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy:factors associated with vision and edema outcomes［J］.Ophthalmology,2018,125(11):1776-1783.
［21］ NICHOLSON L,CROSBY-NWAOBI R,VASCONCELOS J C.Mechanistic evaluation of panretinal photocoagulation versus aflibercept in proliferative diabetic retinopathy:CLARITY substudy［J］.Invest Ophthalmol Vis Sci,2018,59(10):4277-4284.
［22］ ZHAO Y,SINGH R P.The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy［J］.Drugs Context,2018,7:212532.
［23］ BRANISTEANU D C,BILHA A,MORARU A.Vitrectomy surgery of diabetic retinopathy complications［J］.Rom J Ophthalmol,2016,60(1):31-36.
［24］ KLEINMANN G,HAUSER D,SCHECHTMANE,LANDA G,BUKELMAN A,POLLACK A.Vitreous hemorrhage in diabetic eyes previously treated with panretinal photocoagulation［J］.Int Ophthalmol,2008,28(1):29-34.
［25］ SMITH J M,STEEL D H.Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy［J］.Cochrane Database Syst Rev,2015(8):CD008214.
［26］ RUSSO A,LONGO A,AVITABILE T,BONFIGLIO V,FALLICO M,BOSCIA F,et al.Incidence and risk factors for tractional macular detachment after anti-vascular endothelial growth factor agent pretreatment before vitrectomy for complicated proliferative diabetic retinopathy［J］.J Clin Med,2019,8(11):1960.
［27］ KIM K T,JANG J W,KANG S W,CHAE J B,CHO K,BAE K.Vitrectomy combined with intraoperative dexamethasone implant for the management of refractory diabetic macular edema［J］.Korean J Ophthalmol，2019,33(3):249-258.
［28］ KELKAR A,KELKAR J,MEHTA H,AMOAKU W.Cataract surgery in diabetes mellitus:a systematic review［J］.Indian J Ophthalmol，2018,66(10):1401-1410.
［29］ KESSEL L,KOEFOED THEIL P,LYKKE S RENSEN T,MUNCH I C.Cataract surgery in patients with neovascular age-related macular degeneration［J］.Acta Ophthalmol，2016,94(8):755-760.
［30］ ZUR D,IGLICKI M,LOEWENSTEIN A.The role of steroids in the management of diabetic macular edema［J］.Ophthalmic Res，2019,62(4):231-236.
［31］ MANSOUR A M,AL-GHADBAN S I,YUNIS M H,EL-SABBAN M E.Ziv-aflibercept in macular disease［J］.Br J Ophthalmol,2015,99(8):1055-1059.
［32］ KANDASAMY R,CONSTANTINOU M,ROGERS S L,SANDHU S S,WICKREMASINGHE S,AL-QURESHI S,et al.Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery:6-month results［J］.Br J Ophthalmol,2019,103(12):1753-1758.
［33］ WIELDERS L H P,SCHOUTEN J S A G,WINKENS B,VAN DEN BIGGELAARFJHM,VELDHUIZEN C A,MURTA J C N,et al.Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics:ESCRS PREMED Study Report 2［J］.J Cataract Refract Surg,2018,44(7):836-847.
［34］ ZHAO L Q,CHENG J W.A systematic review and meta-analysis of clinical outcomes of intravitreal anti-VEGF agent treatment immediately after cataract surgery for patients with diabetic retinopathy［J］.J Ophthalmol,2019,2019:2648267.
［35］ MIYAKE K,IBARAKI N.Prostaglandins and cystoid macular edema［J］.Surv Ophthalmol,2002,47(Suppl 1):S203-218.
［36］ GONZALEZ-SALINAS R,GUARNIERI A,GUIRAO NAVARRO M C,SAENZ-DE-VITERI M.Patient considerations in cataract surgery-the role of combined therapy using phenylephrine and ketorolac［J］.Patient Prefer Adherence,2016,10:1795-1801.
［37］ COCHEREAU I.Cataract surgery and prostaglandin analogs Yes,but under certain conditions［J］.J Fr Ophthalmol,2004,27(6 Pt 2):706-707.
［38］ KHODABANDEH A,FADAIFARD S,ABDOLLAHI A,KARK-HANEH R,ROOHIPOOR R,ABDI F,et al.Role of combined phacoemulsification and intravitreal injection of bevacizumab in prevention of postoperative macular edema in non-proliferative diabetic retinopathy［J］.J Curr Ophthalmol,2018,30(3):245-249.
［39］ SHARMA M,JAIN N,RANGANATHAN S,SHARMA N,HONAVAR S G,SHARMA N,et al.Tele-ophthalmology:need of the hour［J］.Indian J Ophthalmol,2020,68(7):1328-1338.
相似文献/References:
[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[6]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[7]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[8]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[9]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[10]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[11]曹薇 崔红平 张美萍.23G微切口玻璃体切割手术治疗糖尿病视网膜病变[J].眼科新进展,2013,33(11):000.
[12]徐君,姚丹珍,夏金盈,等.炎症反应在糖尿病视网膜病变中的作用及相关靶点药物的研究进展[J].眼科新进展,2022,42(8):664.[doi:10.13389/j.cnki.rao.2022.0136]
XU Jun,YAO Danzhen,XIA Jinying,et al.Research progress in the role of inflammatory response in diabetic retinopathy and related targeted drugs[J].Recent Advances in Ophthalmology,2022,42(7):664.[doi:10.13389/j.cnki.rao.2022.0136]
[13]邵毅,李乐妍,魏红.糖尿病黄斑水肿的诊断和治疗进展[J].眼科新进展,2022,42(11):841.[doi:10.13389/j.cnki.rao.2022.0174]
SHAO Yi,LI Leyan,WEI Hong.Research progress in diagnosis and treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2022,42(7):841.[doi:10.13389/j.cnki.rao.2022.0174]
[14]朱君雅,姚文,倪锡森,等.糖尿病性黄斑水肿的病理生理机制：神经血管单元研究现状[J].眼科新进展,2023,43(1):066.[doi:10.13389/j.cnki.rao.2023.0014]
ZHU Junya,YAO Wen,NI Xinsen,et al.Pathophysiology of diabetic macular edema: current status of neurovascular unit research[J].Recent Advances in Ophthalmology,2023,43(7):066.[doi:10.13389/j.cnki.rao.2023.0014]
[15]许慕东,朱妍,蔡骐,等.总胆红素水平与糖尿病黄斑水肿发病及严重程度的相关性[J].眼科新进展,2023,43(3):216.[doi:10.13389/j.cnki.rao.2023.0044]
XU Mudong,ZHU Yan,CAI Qi,et al.Correlation between total bilirubin level and occurrence and severity of diabetic macular edema[J].Recent Advances in Ophthalmology,2023,43(7):216.[doi:10.13389/j.cnki.rao.2023.0044]
[16]邵毅,葛倩敏,陈序.糖尿病黄斑水肿患者行醋酸氟轻松治疗规范：2023年专家共识解读[J].眼科新进展,2023,43(10):757.[doi:10.13389/j.cnki.rao.2023.0152]
SHAO Yi,GE Qianmin,CHEN Xu.Specification on the fluocinolone acetonide treatment for patients with diabetic macular edema: interpretation of expert consensus 2023[J].Recent Advances in Ophthalmology,2023,43(7):757.[doi:10.13389/j.cnki.rao.2023.0152]